

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
27 August 2020 (27.08.2020)



(10) International Publication Number
WO 2020/172450 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) A61K 39/00 (2006.01)
A61P 25/28 (2006.01)

(21) International Application Number:
PCT/US2020/019093

(22) International Filing Date:
20 February 2020 (20.02.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/808,141 20 February 2019 (20.02.2019) US

(71) Applicant: **DENALI THERAPEUTICS INC.** [US/US];
161 Oyster Point Blvd., South San Francisco, California
94080 (US).

(72) Inventors: **DENNIS, Mark S.**; c/o Denali Therapeutics
Inc., 161 Oyster Point Blvd., South San Francisco, Cali-
fornia 94080 (US). **DUNCAN, Sherie**; c/o Denali Thera-
peutics Inc., 161 Oyster Point Blvd., South San Francisco,
California 94080 (US). **LISAINGO, Kathleen**; c/o Denali
Therapeutics Inc., 161 Oyster Point Blvd., South San Fran-
cisco, California 94080 (US). **MONROE, Kathryn M.**; c/o
Denali Therapeutics Inc., 161 Oyster Point Blvd., South San
Francisco, California 94080 (US). **PARK, Joshua I.**; c/o
Denali Therapeutics Inc., 161 Oyster Point Blvd., South San
Francisco, California 94080 (US). **PROROK, Rachel**; c/o
Denali Therapeutics Inc., 161 Oyster Point Blvd., South San
Francisco, California 94080 (US). **SHI, Ju**; c/o Denali Ther-
apeutics Inc., 161 Oyster Point Blvd., South San Francisco,
California 94080 (US). **SRIVASTAVA, Ankita**; c/o Denali
Therapeutics Inc., 161 Oyster Point Blvd., South San Fran-
cisco, California 94080 (US). **VAN Lengerich, Betti-
na**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd.,
South San Francisco, California 94080 (US). **WALSH, Ri-
ley**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd.,
South San Francisco, California 94080 (US).

(74) Agent: **YAO, Zhengzheng** et al.; Kilpatrick Townsend &
Stockton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree
Street, Suite 2800, Atlanta, Georgia 30309 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

WO 2020/172450 A1

(54) Title: ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF

(57) Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.